Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Holdings Reduced by Thrivent Financial for Lutherans
Thrivent Financial for Lutherans lowered its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 89.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,424 shares of the biotechnology company’s stock after selling 517,095 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.07% of Sarepta Therapeutics worth $6,690,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Prelude Capital Management LLC grew its stake in Sarepta Therapeutics by 100.2% in the second quarter. Prelude Capital Management LLC now owns 7,008 shares of the biotechnology company’s stock valued at $803,000 after purchasing an additional 3,507 shares in the last quarter. Ossiam lifted its position in shares of Sarepta Therapeutics by 105.0% in the second quarter. Ossiam now owns 1,568 shares of the biotechnology company’s stock worth $180,000 after buying an additional 803 shares during the last quarter. Credit Suisse AG lifted its position in shares of Sarepta Therapeutics by 16.4% in the second quarter. Credit Suisse AG now owns 224,831 shares of the biotechnology company’s stock worth $25,748,000 after buying an additional 31,659 shares during the last quarter. BlackRock Inc. lifted its position in shares of Sarepta Therapeutics by 4.2% in the second quarter. BlackRock Inc. now owns 5,503,466 shares of the biotechnology company’s stock worth $630,257,000 after buying an additional 220,771 shares during the last quarter. Finally, Sectoral Asset Management Inc. lifted its position in shares of Sarepta Therapeutics by 112.3% in the second quarter. Sectoral Asset Management Inc. now owns 52,449 shares of the biotechnology company’s stock worth $6,006,000 after buying an additional 27,739 shares during the last quarter. Hedge funds and other institutional investors own 91.82% of the company’s stock.
Analyst Ratings Changes
SRPT has been the subject of a number of analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $148.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, November 21st. JPMorgan Chase & Co. cut their price objective on Sarepta Therapeutics from $211.00 to $115.00 and set an “overweight” rating for the company in a research report on Tuesday, October 31st. Needham & Company LLC cut their price objective on Sarepta Therapeutics from $185.00 to $82.00 and set a “buy” rating for the company in a research report on Tuesday, October 31st. Mizuho reissued a “buy” rating and set a $160.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, September 26th. Finally, Oppenheimer cut Sarepta Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 31st. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $153.10.
View Our Latest Analysis on SRPT
Sarepta Therapeutics Trading Down 1.6 %
SRPT stock opened at $87.03 on Friday. Sarepta Therapeutics, Inc. has a 1-year low of $55.25 and a 1-year high of $159.89. The firm has a market cap of $8.14 billion, a P/E ratio of -11.11 and a beta of 1.02. The business’s 50 day moving average is $96.41 and its 200-day moving average is $109.75. The company has a current ratio of 5.44, a quick ratio of 4.90 and a debt-to-equity ratio of 1.62.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of ($1.63) by $2.00. The business had revenue of $331.80 million for the quarter, compared to analyst estimates of $285.33 million. Sarepta Therapeutics had a negative return on equity of 46.23% and a negative net margin of 62.52%. Sarepta Therapeutics’s revenue for the quarter was up 44.1% on a year-over-year basis. During the same period in the prior year, the company earned ($2.94) EPS. Equities analysts anticipate that Sarepta Therapeutics, Inc. will post -6.9 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Sarepta Therapeutics news, Director Richard Barry purchased 50,000 shares of the firm’s stock in a transaction that occurred on Friday, November 3rd. The shares were acquired at an average cost of $78.81 per share, for a total transaction of $3,940,500.00. Following the transaction, the director now directly owns 140,000 shares in the company, valued at $11,033,400. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Sarepta Therapeutics news, CEO Douglas S. Ingram purchased 25,225 shares of the firm’s stock in a transaction that occurred on Friday, November 3rd. The shares were acquired at an average cost of $79.36 per share, for a total transaction of $2,001,856.00. Following the transaction, the chief executive officer now directly owns 390,307 shares in the company, valued at $30,974,763.52. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard Barry acquired 50,000 shares of the firm’s stock in a transaction on Friday, November 3rd. The stock was purchased at an average price of $78.81 per share, for a total transaction of $3,940,500.00. Following the completion of the transaction, the director now directly owns 140,000 shares in the company, valued at approximately $11,033,400. The disclosure for this purchase can be found here. 7.40% of the stock is owned by corporate insiders.
Sarepta Therapeutics Profile (Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene.
Further Reading
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Sarepta Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Sarepta Therapeutics wasn’t on the list.
While Sarepta Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.